Cargando…
Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer
The aim of this study was to determine the prognostic value of quantitative fluorodeoxyglucose (FDG) measurements (maximum standardized uptake value [SUV(max)], metabolic tumor volume [MTV], and total lesion glycolysis [TLG]) in patients with newly diagnosed metastatic breast cancer (MBC). An IRB-ap...
Autores principales: | Ulaner, Gary A, Eaton, Anne, Morris, Patrick G, Lilienstein, Joshua, Jhaveri, Komal, Patil, Sujata, Fazio, Maurizio, Larson, Steven, Hudis, Clifford A, Jochelson, Maxine S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892804/ https://www.ncbi.nlm.nih.gov/pubmed/24403238 http://dx.doi.org/10.1002/cam4.119 |
Ejemplares similares
-
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial
por: Iyengar, Neil M., et al.
Publicado: (2019) -
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016) -
The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021) -
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
por: Jhaveri, Komal, et al.
Publicado: (2017) -
Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on (18)fluorine-fluorodeoxyglucose positron emission tomography/computed tomography
por: Das, Jeeban Paul, et al.
Publicado: (2020)